Clinical Trials in Los Angeles

Showing 11521-11540 of 14,465 trials

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

NCT02253550

This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.

Chronic Hepatitis C

Peter J. Ruane, M.D.30 participantsStarted Oct 2014

Los Angeles, California, United States

COMPLETEDPhase 1< 1 mile

Development of Ibudilast for Alcohol Use Disorder

NCT02025998

The objective of this proposal is to advance medication development for alcoholism by conducting a safety and initial efficacy study of ibudilast, a neuroimmune modulator and phosphodiesterase inhibitor, for alcohol use disorders.

Alcohol Use Disorders

University of California, Los Angeles24 participantsStarted Dec 2013

Los Angeles, California, United States

COMPLETEDPhase 4< 1 mile

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636

This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

Hepatitis C, Chronic

Hoffmann-La Roche1,469 participantsStarted Dec 2003

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +129 more locations

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

Development of Ibudilast for Alcohol Use Disorder

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Find Trials by Condition in Los Angeles

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

Intradiscal rhGDF-5 Phase I/II Clinical Trial

Blood and Marrow Transplant Clinical Research Network

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

GORE Flow Reversal System and GORE Embolic Filter Extension Study

Relapse Prevention Study in Newly Abstinent Smokers

Atacicept in Subjects With Optic Neuritis

Glucose Meter Study